<< Switching to new immunosuppressant drug may reduce skin cancer after kidney transplantation | India pharmaceuticals and healthcare report from Research and Markets >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | עִבְרִית | Русский | Svenska | Polski

New report on China's pharmaceuticals and healthcare industry

Published on November 2, 2009 at 1:41 AM · No Comments

Research and Markets (http://www.researchandmarkets.com/research/dbe80f/china_pharmaceutic) has announced the addition of the "China Pharmaceuticals and Healthcare Report Q4 2009" report to their offering.

The China Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on China's pharmaceuticals and healthcare industry.

In BMI's view, China is arguably the most attractive emerging pharmaceutical market. Though to 2013, we are forecasting a compound annual growth rate (CAGR) of 15.45%. Annual per-capita spending will rise from US$27.60 to US$54.40. Spending as a percent of GDP is expected to increase from 0.97% to 1.16%. Key drivers of market expansion are the introduction of universal health insurance, a booming economy, more chronic diseases, and an ageing population. By 2018, annual pharmaceutical sales will have reached a staggering US$132.7bn.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading